Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Inorg Biochem. 2012 Apr;109:82-9. doi: 10.1016/j.jinorgbio.2011.12.011. Epub 2011 Dec 30.

Is DTPA a good competing chelating agent for Th(IV) in human serum and suitable in targeted alpha therapy?

Author information

  • 1Laboratoire SUBATECH, UMR Ecole des Mines/CNRS/In2p3/Universit√© de Nantes, 4 rue A. Kastler, BP 20722, 44307 Nantes cedex 03, France.

Abstract

The interaction between thorium and human serum components was studied using difference ultraviolet spectroscopy (DUS), ultrafiltration and high-pressure-anion exchange chromatography (HPAEC) with external inductively conducted plasma mass spectrometry (ICP-MS) analysis. Experimental data are compared with modelling results based on the law of mass action. Human serum transferrin (HSTF) interacts strongly with Th(IV), forming a ternary complex including two synergistic carbonate anions. This complex governs Th(IV) speciation under blood serum conditions. Considering the generally used Langmuir-type model, values of 10(33.5) and 10(32.5) were obtained for strong and weak sites, respectively. We showed that trace amounts of diethylene triamine pentaacetic acid (DTPA) cannot complex Th(IV) in the blood serum at equilibrium. Unexpectedly this effect is not related to the competition with HSTF but is due to the strong competition with major divalent metal ions for DTPA. However, Th-DTPA complex was shown to be stable for a few hours when it is formed before addition in the biological medium; this is related to the high kinetic stability of the complex. This makes DTPA a potential chelating agent for synthesis of (226)Th-labelled biomolecules for application in targeted alpha therapy.

Copyright © 2011 Elsevier Inc. All rights reserved.

PMID:
22388013
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk